Atypical antipsychotic medications increase postprandial triglyceride and glucose levels in male rats: Relationship with stearoyl-CoA desaturase activity

Schizophrenia Research

Volumn 129, Issue 1, 2011, Pages 66-73

  McNamara, Robert K ^a   Jandacek, Ronald ^a   Rider, Therese ^a   Tso, Patrick ^a   Cole Strauss, Allyson ^a   Lipton, Jack W ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Desaturation index; Erythrocytes; Glucose; Insulin; Liver; Oleic acid; Postprandial; Rat; Stearoyl CoA desaturase 1; Triglycerides

Indexed keywords

ACYL COENZYME A DESATURASE; GLUCOSE; HALOPERIDOL; INSULIN; OLANZAPINE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PALIPERIDONE; POLYUNSATURATED FATTY ACID; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; ERYTHROCYTE MEMBRANE; FATTY ACID SYNTHESIS; GLUCOSE BLOOD LEVEL; HEART MUSCLE FIBER MEMBRANE; INSULIN BLOOD LEVEL; LIPID COMPOSITION; LIVER; MALE; NONHUMAN; PHOSPHOLIPID MEMBRANE; POSTPRANDIAL STATE; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTIPSYCHOTIC AGENTS; DRINKING WATER; GLUCOSE; LIVER; MALE; POSTPRANDIAL PERIOD; RATS; RATS, LONG-EVANS; RNA, MESSENGER; STEAROYL-COA DESATURASE; TRIGLYCERIDES;

EID: 79956088603     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.03.016     Document Type: Article

References (58)

1. Andersson C., Hamer R.M., Lawler C.P., Mailman R.B., Lieberman J.A. Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs. Neuropsychopharmacology 2002, 27:143-151.
2. Attie A.D., Krauss R.M., Gray-Keller M.P., Brownlie A., Miyazaki M., Kastelein J.J., Lusis A.J., Stalenhoef A.F., Stoehr J.P., Hayden M.R., Ntambi J.M. Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J. Lipid Res. 2002, 43:1899-1907.
3. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298:309-316.
4. Best L., Yates A.P., Reynolds G.P. Actions of antipsychotic drugs on pancreatic beta-cell function: contrasting effects of clozapine and haloperidol. J. Psychopharmacol. 2005, 19:597-601.
5. Betz A., Ishiwari K., Wisniecki A., Huyn N., Salamone J.D. Quetiapine (Seroquel) shows a pattern of behavioral effects similar to the atypical antipsychotics clozapine and olanzapine: studies with tremulous jaw movements in rats. Psychopharmacol. Berl. 2005, 179:383-392.
6. Caniato R.N., Alvarenga M.E., Garcia-Alcaraz M.A. Effect of omega-3 fatty acids on the lipid profile of patients taking clozapine. Aust. N Z J. Psychiatry 2006, 40:691-697.
7. Cooper G.D., Pickavance L.C., Wilding J.P., Harrold J.A., Halford J.C., Goudie A.J. Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J. Psychopharmacol. 2007, 21:405-413.
8. Childs C.E., Romeu-Nadal M., Burdge G.C., Calder P.C. The polyunsaturated fatty acid composition of hepatic and plasma lipids differ by both sex and dietary fat intake in rats. J. Nutr. 2010, 140:245-250.
9. Eberly L.E., Stamler J., Neaton J.D., Multiple Risk Factor Intervention Trial Research Group Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch. Intern. Med. 2003, 163:1077-1083.
10. Fernø J., Raeder M.B., Vik-Mo A.O., Skrede S., Glambek M., Tronstad K.J., Breilid H., Løvlie R., Berge R.K., Stansberg C., Steen V.M. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?. Pharmacogenomics J. 2005, 5:298-304.
11. Flowers M.T., Ntambi J.M. Stearoyl-CoA desaturase and its relation to high-carbohydrate diets and obesity. Biochim. Biophys. Acta 2009, 1791:85-91.
12. García-Serrano S., Moreno-Santos I., Garrido-Sánchez L., Gutierrez-Repiso C., García-Almeida J.M., García-Arnés J., Rivas-Marín J., Gallego-Perales J.L., García-Escobar E., Rojo-Martinez G., Tinahones F., Soriguer F., Macias-Gonzalez M., García-Fuentes E. Stearoyl-CoA desaturase-1 is associated with insulin resistance in morbidly obese subjects. Mol. Med. 2010, [Epub ahead of print].
13. Garman P.M., Ried L.D., Bengtson M.A., Hsu C., McConkey J.R. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia. J. Am. Pharm. Assoc. 2007, 47:373-378.
14. Hassanali Z., Ametaj B.N., Field C.J., Proctor S.D., Vine D.F. Dietary supplementation of n-3 PUFA reduces weight gain and improves postprandial lipaemia and the associated inflammatory response in the obese JCR:LA-cp rat. Diab. Obes. Metab. 2010, 12:139-147.
15. Henderson D.C. Weight gain with atypical antipsychotics: evidence and insights. J. Clin. Psychiatry 2007, 68:18-26.
16. Hulver M.W., Berggren J.R., Carper M.J., Miyazaki M., Ntambi J.M., Hoffman E.P., Thyfault J.P., Stevens R., Dohm G.L., Houmard J.A., Muoio D.M. Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. Cell Metab. 2005, 2:251-261.
17. Issandou M., Bouillot A., Brusq J.M., Forest M.C., Grillot D., Guillard R., Martin S., Michiels C., Sulpice T., Daugan A. Pharmacological inhibition of stearoyl-CoA desaturase 1 improves insulin sensitivity in insulin-resistant rat models. Eur. J. Pharmacol. 2009, 618:28-36.
18. Landschulz K.T., Jump D.B., MacDougald O.A., Lane M.D. Transcriptional control of the stearoyl-CoA desaturase-1 gene by polyunsaturated fatty acids. Biochem. Biophys. Res. Commun. 1994, 200:763-768.
19. Langsted A., Freiberg J.J., Nordestgaard B.G. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008, 118:2047-2056.
20. Lauressergues E., Staels B., Valeille K., Majd Z., Hum D.W., Duriez P., Cussac D. Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes. Naunyn-Schmiedebergs Arch. Pharmacol. 2010, 381:427-439.
21. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
22. Lu J., Borthwick F., Hassanali Z., Wang Y., Mangat R., Ruth M., Shi D., Jaeschke A., Russell J.C., Field C.J., Proctor S.D., Vine D.F. Chronic dietary n-3 PUFA intervention improves dyslipidaemia and subsequent cardiovascular complications in the JCR:LA-cp rat model of the metabolic syndrome. Br. J. Nutr. 2011, 31:1-11.
23. Mangravite L.M., Dawson K., Davis R.R., Gregg J.P., Krauss R.M. Fatty acid desaturase regulation in adipose tissue by dietary composition is independent of weight loss and is correlated with the plasma triacylglycerol response. Am. J. Clin. Nutr. 2007, 86:759-767.
24. Mar-Heyming R., Miyazaki M., Weissglas-Volkov D., Kolaitis N.A., Sadaat N., Plaisier C., Pajukanta P., Cantor R.M., de Bruin T.W., Ntambi J.M., Lusis A.J. Association of stearoyl-CoA desaturase 1 activity with familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1193-1199.
25. McNamara R.K., Sullivan J., Richtand N.M. Omega-3 fatty acid deficiency augments the development of behavioral sensitization in adult mice: prevention by chronic lithium treatment. J. Psychiatr. Res. 2008, 42:458-468.
26. McNamara R.K., Able J.A., Jandacek R., Rider T., Tso P. Chronic risperidone treatment preferentially increases rat erythrocyte and prefrontal cortex omega-3 fatty acid composition: evidence for augmented biosynthesis. Schizophr. Res. 2009, 107:150-157.
27. McNamara R.K., Able J.A., Liu Y., Jandacek R., Rider T., Tso P. Gender differences in rat erythrocyte and brain docosahexaenoic acid composition: role of ovarian hormones and dietary omega-3 fatty acid composition. Psychoneuroendocrinology 2009, 34:532-539.
28. McNamara R.K., Rider T., Jandacek R., Tso P., Cole-Strauss A., Lipton J.W. Differential effects of antipsychotic medications on polyunsaturated fatty acid biosynthesis in rats: relationship with liver delta6-desaturase expression. Schizophr. Res. 2011, [Epub ahead of print].
29. Meyer J.M., Davis V.G., McEvoy J.P., Goff D.C., Nasrallah H.A., Davis S.M., Daumit G.L., Hsiao J., Swartz M.S., Stroup T.S., Lieberman J.A. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr. Res. 2008, 103:104-109.
30. Meyer J.M., Koro C.E. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res. 2004, 70:1-17.
31. Meyer J.M. Effects of atypical antipsychotics on weight and serum lipid levels. J. Clin. Psychiatry 2001, 62:27-34.
32. Migler B.M., Warawa E.J., Malick J.B. Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacol. Berl. 1993, 112:299-307.
33. Minet-Ringuet J., Even P.C., Goubern M., Tomé D., de Beaurepaire R. Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration. Appetite 2006, 46:254-262.
34. Miyazaki M., Kim Y.C., Gray-Keller M.P., Attie A.D., Ntambi J.M. The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1. J. Biol. Chem. 2000, 275:30132-30138.
35. Miyazaki M., Kim Y.C., Ntambi J.M. A lipogenic diet in mice with a disruption of the stearoyl-CoA desaturase 1 gene reveals a stringent requirement of endogenous monounsaturated fatty acids for triglyceride synthesis. J. Lipid Res. 2001, 42:1018-1024.
36. Muhlhausler B.S., Cook-Johnson R., James M., Miljkovic D., Duthoit E., Gibson R. Opposing effects of omega-3 and omega-6 long chain polyunsaturated Fatty acids on the expression of lipogenic genes in omental and retroperitoneal adipose depots in the rat. J Nutr Metab. 2010, [Epub ahead of print].
37. Mustad V.A., Demichele S., Huang Y.S., Mika A., Lubbers N., Berthiaume N., Polakowski J., Zinker B. Differential effects of n-3 polyunsaturated fatty acids on metabolic control and vascular reactivity in the type 2 diabetic ob/ob mouse. Metabolism 2006, 55:1365-1374.
38. Newcomer J.W. Antipsychotic medications: metabolic and cardiovascular risk. J. Clin. Psychiatry 2007, 68:8-13.
39. Newcomer J.W., Haupt D.W., Fucetola R., Melson A.K., Schweiger J.A., Cooper B.P., Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry 2002, 59:337-345.
40. Ntambi J.M., Miyazaki M., Stoehr J.P., Lan H., Kendziorski C.M., Yandell B.S., Song Y., Cohen P., Friedman J.M., Attie A.D. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc. Natl Acad. Sci. U.S.A. 2002, 99:11482-11486.
41. Ntambi J.M. Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol. J. Lipid Res. 1999, 40:1549-1558.
42. Ota M., Mori K., Nakashima A., Kaneko Y.S., Fujiwara K., Itoh M., Nagasaka A., Ota A. Peripheral injection of risperidone, an atypical antipsychotic, alters the bodyweight gain of rats. Clin. Exp. Pharmacol. Physiol. 2002, 29:980-989.
43. Paillard F., Catheline D., Duff F.L., Bouriel M., Deugnier Y., Pouchard M., Daubert J.C., Legrand P. Plasma palmitoleic acid, a product of stearoyl-coA desaturase activity, is an independent marker of triglyceridemia and abdominal adiposity. Nutr. Metab. Cardiovasc. Dis. 2008, 18:436-440.
44. Paton C.M., Ntambi J.M. Biochemical and physiological function of stearoyl-CoA desaturase. Am. J. Physiol. Endocrinol. Metab. 2009, 297:28-37.
45. Peet M., Horrobin D.F., E-E Multicentre Study Group A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J. Psychiatr. Res. 2002, 36:7-18.
46. Pérez C., Canal J.R., Domínguez E., Campillo J.E., Guillén M., Torres M.D. Individual housing influences certain biochemical parameters in the rat. Lab Anim. 1997, 31:357-361.
47. Polymeropoulos M.H., Licamele L., Volpi S., Mack K., Mitkus S.N., Carstea E.D., Getoor L., Thompson A., Lavedan C. Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia. Schizophr. Res. 2009, 108:134-142.
48. Raeder M.B., Fernø J., Vik-Mo A.O., Steen V.M. SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects?. Mol. Cell. Biochem. 2006, 289:167-173.
49. Rahman S.M., Dobrzyn A., Dobrzyn P., Lee S.H., Miyazaki M., Ntambi J.M. Stearoyl-CoA desaturase 1 deficiency elevates insulin-signaling components and down-regulates protein-tyrosine phosphatase 1B in muscle. Proc. Natl Acad. Sci. U.S.A. 2003, 100:11110-11115.
50. Sasaki N., Iwase M., Uchizono Y., Nakamura U., Imoto H., Abe S., Iida M. The atypical antipsychotic clozapine impairs insulin secretion by inhibiting glucose metabolism and distal steps in rat pancreatic islets. Diabetologia 2006, 49:2930-2938.
51. Sessler A.M., Kaur N., Palta J.P., Ntambi J.M. Regulation of stearoyl-CoA desaturase 1 mRNA stability by polyunsaturated fatty acids in 3T3-L1 adipocytes. J. Biol. Chem. 1996, 271:29854-29858.
52. Smith R.C., Lindenmayer J.P., Davis J.M., Kelly E., Viviano T.F., Cornwell J., Hu Q., Khan A., Vaidhyanathaswamy S. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. J. Clin. Psychiatry 2009, 70:1501-1513.
53. Smith R.C., Lindenmayer J.P., Hu Q., Kelly E., Viviano T.F., Cornwell J., Vaidhyanathaswamy S., Marcovina S., Davis J.M. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study. Schizophr. Res. 2010, 120:204-209.
54. Tarazi F.I., Zhang K., Baldessarini R.J. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacol. Berl. 2002, 161:263-270.
55. Terry A.V., Gearhart D.A., Mahadik S.P., Warsi S., Davis L.W., Waller J.L. Chronic exposure to typical or atypical antipsychotics in rodents: temporal effects on central alpha7 nicotinic acetylcholine receptors. Neuroscience 2005, 136:519-529.
56. Uto Y., Ogata T., Kiyotsuka Y., Ueno Y., Miyazawa Y., Kurata H., Deguchi T., Watanabe N., Konishi M., Okuyama R., Kurikawa N., Takagi T., Wakimoto S., Ohsumi J. Novel benzoylpiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl) amide and its plasma triglyceride-lowering effects in Zucker fatty rats. Bioorg. Med. Chem. Lett. 2010, 20:341-345.
57. Vik-Mo A.O., Birkenaes A.B., Fernø J., Jonsdottir H., Andreassen O.A., Steen V.M. Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. Int. J. Neuropsychopharmacol. 2008, 11:679-684.
58. Warensjö E., Ingelsson E., Lundmark P., Lannfelt L., Syvänen A.C., Vessby B., Risérus U. Polymorphisms in the SCD1 gene: associations with body fat distribution and insulin sensitivity. Obesity 2007, 15:1732-1740.